Announces 52-Week Interim Data From Its Global Phase I/II Study Of JR-171 In Individuals With MPS I
29/09/2023 08:02
Sept 29 (Reuters) - JCR Pharmaceuticals Co Ltd 4552.T :
* JCR PHARMACEUTICALS CO LTD - ANNOUNCES 52-WEEK INTERIM
DATA FROM
ITS GLOBAL PHASE I/II STUDY OF JR-171 IN INDIVIDUALS WITH MPS I
Source text for Eikon: ID:nTSuc88f0b
Further company coverage: 4552.T
Recent news on JCR Pharmaceuticals
See all newsBrief: JCR Pharmaceuticals Receives Marketing Authorization In Kuwait For Izcargo
Italfarmaco And Jcr Pharmaceuticals Enter Into Exclusive License Agreement For Jr-141 In United States, Europe, And Latin America
Brief: Jcr Pharmaceuticals Receives Orphan Drug Designation For Givinostat In Japan
Brief: Medipal & JCR Dose First Patient In Global Phase I/II Trial OF JR-446 For Mucopolysaccharidosis Type IIIB
Table: Jcr Pharmaceuticals -Q1 group results